Enforcement Directorate’s investigation reveals massive narco-trafficking network involving 2.24 crore bottles, corrupt officials, and pharmaceutical giants
A sprawling narcotic smuggling operation has been completely exposed following an extensive Enforcement Directorate investigation into a syndicate illegally trafficking cough syrup across India and into Bangladesh. The probe has uncovered a sophisticated criminal network involving pharmaceutical manufacturers, corrupt government officials, and politicians—unveiling one of the largest illicit cough syrup operations in recent years.
The Scale of the Scam
The investigation revealed that Shubham Jaiswal and his father Bhola Jaiswal orchestrated the smuggling of 2.24 crore (22.4 million) bottles of narcotic cough syrup through a Ranchi-based firm called Shaili Traders. The entire operation was valued at over Rs 500 crore, making it one of the most significant pharmaceutical smuggling cases in the country.
The contraband syrup was systematically routed through Tripura before being smuggled into Bangladesh, creating an international trafficking network that evaded detection for an extended period.
How the Operation Functioned
The ED’s investigation uncovered a meticulously planned scheme to mask the illegal movement of syrup. The accused created fake billing across 177 shell companies spread across 13 districts in Uttar Pradesh. This elaborate web of fictitious firms served as a cover for the actual supply chain, allowing the smugglers to maintain plausible deniability while moving massive quantities of controlled substances.
“Documents recovered during raids contain detailed records of the operation’s mechanics,” ED officials revealed during the investigation.
The Corruption Network
What makes this case particularly alarming is the extent of official complicity. During raids on the premises of Shubham Jaiswal and his chartered accountant Vishnu Agarwal, ED officials recovered documents detailing payments made to more than half a dozen politicians, a prominent mafia figure, and two drug inspectors. This suggests a well-entrenched corruption network that actively facilitated the smuggling operation.
The involvement of drug inspectors appears especially significant. Investigators suspect that these officials provided Shubham with information about defunct pharmaceutical firms and companies whose licenses had been revoked—critical intelligence that enabled the fake billing scheme to succeed without raising regulatory red flags.
The Pharmaceutical Connection
The investigation has implicated multiple pharmaceutical manufacturers in the scheme. Abbott India, the multinational pharmaceutical giant with facilities in Baddi, Himachal Pradesh, emerges as the largest supplier of Phensedyl syrup to the smuggling network. Abbott initially supplied the syrup to other distributors, but when their consignments began getting seized, the company appointed Shubham Jaiswal as their super stockist.
This arrangement continued for an extended period, raising questions about the company’s due diligence and oversight mechanisms. Laboart Pharma, also based in Paonta Sahib, Himachal Pradesh, has similarly come under scrutiny for its role in the operation.
Police authorities are preparing to file FIRs against these pharmaceutical companies for manufacturing and supplying illicit cough syrup, with plans to designate the accused individuals as their super stockists.
The Fugitive
A significant complication in the case is the flight of Shubham Jaiswal to Dubai, allegedly with the protection of politicians and mafia connections. The ED has announced plans to issue a Red Corner Notice against him, signalling its intent to seek international cooperation in his extradition.
Investigation Continues
The probe is far from complete. ED officials are currently investigating drug inspectors who were posted in Varanasi over the past three years, with plans to question them regarding their alleged involvement in facilitating the smuggling network. The recovery of detailed financial records from Shubham’s ancestral home is expected to provide additional leads into the broader corruption ecosystem that enabled this operation.
The case represents a significant breakdown in regulatory oversight and government accountability, exposing how organized criminal networks can exploit pharmaceutical supply chains with the complicity of officials sworn to prevent such activities.
Leave a Reply